Saudi FDA: Working with Industry to Improve the Reporting of Adverse Reactions

Andrea Charles

In this interview Dr. Nasser Al-Qahtani, Head, Adverse Drug Reactions Evaluation Department Saudi FDA speaks to Andrea Charles from Pharma IQ, about the Saudi FDA pharmacovigilance system and what new guidelines he predicts will be areas for discussion amongst pharma/bio companies in 2012. Dr. Nasser Al-Qahtani shares his insights on the impact of social media on the pharmacovigilance system and the initiatives the Saudi FDA are planning to imple...
To continue reading this story get free access